A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Palbociclib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 29 Jun 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jul 2018.
- 19 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 Oct 2017 Planned End Date changed from 1 Apr 2024 to 1 Feb 2024.